SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG Crypto is trending as holders highlight the passive income potential through Solana rewards, which are distributed based on transaction volume; the community emphasizes the project's resilience, community ownership, and utility beyond a typical meme coin; upcoming developments, including participation in a Solana hackathon and the launch of a live auditing dashboard, are generating excitement.

Wenlive provides free, open access to decentralized streaming for any creator with a Solana wallet — no KYC, no platform lock-in, and no gatekeeping. It lowers the barrier for global creators to earn on-chain and reach new audiences. Key infrastructure like token-gating, stream metadata, and referral tracking will be open-sourced to support other Solana-based creator tools. Wenlive strengthens the creator economy and promotes censorship-resistant, community-owned media on Solana.

wenlive.fun

WENLIVE is trending as the community highlights activity involving Phantom Wallet. Conversations suggest positive sentiment and potential upward momentum, with some users emphasizing 'moon vibes'. The crypto is also being discussed in relation to BTC and SOL.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto community discusses the impact of potential US-China trade resolutions and their impact on the market. Discussions revolve around whether recent price movements indicate a bull trap or a genuine recovery, with some traders pointing to technical indicators while others express skepticism about market manipulation. The potential for new all-time highs is also being weighed against concerns of over-leveraged positions and the influence of political factors.

JERRY (JYAI) is a Matt Furie's artistic style; it features an AI-powered content creation hub that produces community-driven video series and art.  Jerry the Turtle, created by Matt Furie, is a character inspired by Furie’s artistic style. JERRY is also an AI-driven meme coin with an ambitious vision. The goal is to establish an AI-powered production house dedicated to creating a video series or episodes featuring characters from Matt Furie’s universe alongside those from Jerry’s world.  This unique blend of characters aims to produce the ultimate crypto-based series. Additionally, we are developing an app that will offer an exclusive, ad-free video series featuring characters from both Matt Furie’s creations and the Jerry Universe. Users will be able to download and share videos directly through the platform.  But that’s not all! A special Jerry Art Panel will showcase original Jerry characters, artwork, and fan creations—free to explore, download, and share with the community.

Jerry The Turtle By Matt Furie

JYAI (Jerry The Turtle By Matt Furie) is trending amid community excitement surrounding new listings and exchange integrations, including a recent bridge to BNB. The community highlights the coin's association with Matt Furie and draws comparisons to other successful meme coins, with some suggesting a potential Binance listing and anticipating further growth.

Typen is Crynode's first MVP AI Agent designed to interact with both people and other AI agents. It leverages a combination of state-of-the-art AI models and advanced machine learning techniques to think, analyze, and navigate the Solana blockchain. Typen’s architecture is custom-built and advanced, setting it apart from starter frameworks like Eliza (ai16z), as shown by the depth of his responses. He’s built for head-to-head competition with shallow AIs like $goat (Terminal of Truths), aiming to provide real value rather than just entertainment. Typen represents the first pillar of Crynode's long-term vision: a future where high-quality AIs cooperate with humans to create sustainable, long-term wealth.

Typen

Typen is gaining attention, particularly among Phantom Wallet users, with many highlighting increased volume and potential breakouts. The community is using phrases like "moon vibes" and suggesting that early entry could be advantageous. Mentions of other cryptos like SOL and BTC suggest that Typen may be riding on the overall crypto market.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to its low float and recent price action, leading to speculation about a potential squeeze. The community is actively discussing entry points and anticipating a significant upward move, with some comparing it to other low-float stocks that have experienced substantial gains. Bullish sentiment is fueled by the stock appearing on top watchers lists and discussions around potential breakouts.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph ($HBAR) is trending as the community discusses potential catalysts like rate cuts, ETF possibilities, and the broader context of a possible altcoin season. Community members are actively debating market manipulation and optimal entry points, while also monitoring news related to tariffs and institutional investment. Discussion includes the potential impact of government actions and broader market trends on HBAR's price.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins ($PENGU) is trending amidst community discussions about potential ETF approvals and recent market volatility. Traders are actively debating entry points following a recent dip, while some express confidence in a future rally. The community is also closely watching for updates related to partnerships and developments surrounding the project.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as traders discuss a significant market shakeup and mass liquidations affecting many crypto accounts, with some seeing it as a buying opportunity. Community members are debating the causes and potential recovery, while also highlighting specific Solana-based tokens and projects like $WENLIVE, $TYPEN, and $UPDOG. There's also discussion of new projects, airdrops and potential for Solana to outperform ETH.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as traders discuss the impact of recent market volatility, with some pointing to a potential "shakeout" of leveraged positions and others highlighting accumulation opportunities. Community members are debating short-term trading strategies versus long-term holding, while also monitoring broader market cues and potential regulatory developments. The conversation includes speculation around institutional activity and the potential for a market recovery.

statis crypto Watchlist

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

H.C. Wainwright on Tuesday raised its price target on MannKind to $11 from $9 and reiterated its buy rating on the shares, following positive late-stage study results from partner United Therapeutics for its Tyvaso Inhalation Solution.The brokerage firm said the positive data removes “a significant overhang” on MannKind shares and supports a re-rating of the stock toward intrinsic value, with added upside from royalties and cash flows tied to Tyvaso.The call comes after United Therapeutics said Tuesday that its phase 3 TETON-2 trial showed nebulized Tyvaso improved lung function in idiopathic pulmonary fibrosis patients versus placebo in a dose-dependent manner, meeting the trial's primary endpoint.&nbsp;Over 52 weeks, patients on Tyvaso saw lung capacity improve by 95.6 milliliters compared with placebo, a result the company said was highly statistically significant.&nbsp;Benefits were observed across patient subgroups, and significant gains were also reported in quality of life and other secondary measures. The treatment was well-tolerated with no new safety signals.United Therapeutics said it plans to meet with the U.S. Food and Drug Administration before the end of the year to discuss adding IPF to Tyvaso’s label, with additional data from the ongoing TETON-1 study expected in the first half of 2026.Last week, MannKind said that United Therapeutics had exercised an option under their 2018 license and collaboration agreement to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">develop a second dry powder inhalation therapy</a>. The partnership previously produced Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension, cleared in 2022.MannKind will use its Technosphere platform to formulate a new investigational molecule, while United Therapeutics will conduct preclinical and clinical testing. MannKind will receive $5 million upfront, up to $35 million in milestone payments, and a 10% royalty on sales if the therapy reaches market.&nbsp;On Stocktwits, retail sentiment for both MannKind and United Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.One user speculated that United Therapeutics’ growing ties to MannKind reduce the likelihood of a buyout by another large pharmaceutical company, saying they expect a 13G filing showing a bigger ownership stake.&nbsp;<stembedurl>https://stocktwits.com/Hard2beLong/message/627299899</stembedurl>Another user questioned whether it made more sense for United Therapeutics to continue paying MannKind a 10% royalty stream each year rather than pursue a full acquisition.<stembedurl>https://stocktwits.com/Lazarus2024/message/627294687</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 10.7% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> has risen 14.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

H.C. Wainwright on Tuesday raised its price target on MannKind (MNKD) to $11 from $9 and reiterated its buy rating on the shares. (Photo credit: Getty Images)

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results 

United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary fibrosis to Tyvaso’s label.

Equity

MannKind Corporation (MNKD) on Wednesday said that it will formulate a dry powder inhalation therapy, and United Therapeutics (UTHR) will conduct preclinical and clinical development under an expanded agreement.The two companies entered into a licence and collaboration agreement in 2018. The agreement led to the US Food and Drug Administration’s approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. Tyvaso DPI was the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of MNKD traded 5% higher in the pre-market session at the time of writing.Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/UTHR">UTHR</a> stayed within ‘neutral’ territory, coupled with ‘low’ levels of retail chatter.MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/27/3139981/29517/en/MannKind-Announces-Expansion-of-United-Therapeutics-Collaboration-for-Second-Inhaled-Therapy.html">said</a> that this next step in the collaboration between the two companies strengthens the existing partnership and the versatility of its dry powder formulations.The company said that it will receive an upfront payment of $5 million under the expanded agreement. It is also eligible to receive up to $35 million milestone payments and 10% royalties on net sales of resulting products.Formulation and development activities for the new investigational molecule will begin immediately, the company said. It will be formulated using MannKind’s proprietary Technosphere inhalation technology.While MNKD stock is down by 37% this year, UTHR stock is down by 12%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together

The 2018 agreement between the companies led to US FDA approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. 

New Strong Sell Stocks for August 27th

CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.

Wall Street issued mixed calls on scPharmaceuticals on Monday after MannKind said it would buy the former in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met.&nbsp;The deal represents a 31% premium to scPharma’s last closing price before the announcement.After the news, Craig-Hallum pulled back its rating on scPharmaceuticals, shifting it from ‘Buy’ to ‘Hold’ and setting a price target of $6.&nbsp;Craig-Hallum noted that shareholders are entitled to receive $5.35 in cash per share, along with the potential to receive up to an additional $1 in cash per share from future milestone payments and the firm expects a majority of the CVR value to be paid out over time.Maxim Group also downgraded scPharmaceuticals to ‘Hold’ from ‘Buy’ following the acquisition agreement under the same terms.By contrast, H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with a $9 price target, saying the acquisition strengthens MannKind’s revenue base and expands its reach into cardiorenal medicine. The firm described the price paid as “very reasonable.”The acquisition gives&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">MannKind access to Furoscix</a>, scPharma’s FDA-approved on-body infuser delivering furosemide to treat fluid overload in patients with chronic heart failure and chronic kidney disease.&nbsp;MannKind estimates Furoscix has a total addressable U.S. market of more than $10 billion.scPharma has been expanding its commercial footprint, reporting $27.8 million in net sales for the first half of 2025, a 96% increase year over year, driven by a larger sales force, growth in nephrology, and new integrated delivery network accounts.&nbsp;Its Furoscix ReadyFlow Autoinjector is expected to be filed for FDA approval in the third quarter of 2025, potentially reducing administration time from five hours to less than 10 seconds.The deal is expected to close in the fourth quarter of 2025 pending regulatory approval.&nbsp;At closing, MannKind will also repay and retire scPharma’s credit facility and revenue-sharing obligations to Perceptive, totaling about $81 million if completed by Sept. 30, 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment was ‘extremely bullish’ for scPharmaceuticals with ‘extremely high’ message volume, while sentiment for MannKind was ‘bullish’ with ‘high’ message volume.One user remarked that it was unusual to see a smaller company like MannKind buying a larger one, calling the deal “bizarro territory.”<stembedurl>https://stocktwits.com/Kuka/message/626521368</stembedurl>Another user noted that the acquisition would eliminate scPharmaceuticals’ heavy sales and marketing costs, saying they were beginning to appreciate the efficiency gains MannKind could achieve by folding those operations into its own.<stembedurl>https://stocktwits.com/oneyedjacks/message/626485594</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SCPH">scPharmaceuticals’ stock</a> has risen nearly 56% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined nearly 40% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind (MNKD) said it would buy scPharmaceuticals (SCPH) in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met. (Photo credit: Getty Images)

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.Under the merger agreement, MannKind will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock for $5.35 per share in cash at closing, in addition to one contingent value right worth up to $1. The non-tradeable CVR is payable upon achieving certain regulatory and net sales milestones, the companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth">said</a>.The total per-share consideration of up to $6.35 represents a premium of about 31% to SCPH’s closing price on Friday. The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MannKind</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/SCPH">SCPH stock</a> jumped from ‘neutral’ to ‘bullish’ territory, accompanied by ‘low’ levels of retail chatter. While shares of MannKind traded 5% lower in the pre-market session, SCPH stock traded 13% higher.scPharmaceuticals currently markets Furoscix, an FDA-approved on-body infuser delivering Furosemide, used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD). MannKind, which estimates Furoscix has a total addressable market of over $10 billion in the U.S., said that the acquisition will expand its reach into cardiorenal medicine.MannKind also stated that the combined company is expected to have a stronger revenue base with three commercial assets, including Furoscix.While MNKD stock is down by 36% this year, SCPH stock is up by 37%.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-stock-sees-retail-chatter-spike-340-ahead-of-earnings/chssFwcRd1Y">Alibaba Stock Sees Retail Chatter Spike 340% Ahead Of Earnings: AI Investment And E-Commerce In Focus</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with funds managed by Blackstone (BX) after its second-quarter (Q2) revenue missed Wall Street expectations.“The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes,” MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-blackstone-announce-500-million-strategic-financing">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_8_42_13_AM_png_d534b5d4d1.webp" alt="MNKD's Sentiment Meter and Message Volume as of 8:24 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>MNKD's Sentiment Meter and Message Volume as of 8:24 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure>Afrezza is an inhaled insulin that starts lowering blood sugars in about 12 minutes for adults living with type 1 or type 2 diabetes. The company is now looking to expand its use to pediatric patients, and a U.S. Food and Drug Administration ruling on the application is expected in early our third quarter.The up to $500 million senior secured credit facility consists of a $75 million initial term loan funded at closing, a $125 million delayed draw term loan (DDTL) available for the next 24 months, subject to customary drawdown conditions, and an additional $300 million uncommitted DDTL available at the mutual agreement of MannKind and Blackstone.MNKD stock is down by 40% this year and by about 24% over the past 12 months.A Stocktwits user opined that the stock is ‘ridiculously undervalued’.<stembedurl>https://stocktwits.com/Keeportrade/message/623911248</stembedurl>Another opined that they were hoping for a partnership announcement from the company over a loan.<stembedurl>https://stocktwits.com/Jaketom/message/623908336</stembedurl>MannKind on Wednesday reported Q2 revenues of $76.5 million, marking a growth of 6% year-on-year (YoY) but below an analyst estimate of $77.82 million. &nbsp;&nbsp;&nbsp;&nbsp;The YoY increase was spurred by an increase in royalties and Afrezza revenue, which offset a decline in collaborations and services revenues and a dip in net revenue for V-Go, the company's wearable insulin delivery device.Adjusted net income came in at $0.05 for the three months through the end of June, in line with estimates.MNKD stock is down by 38% this year and by 24% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-plans-shut-down-of-illinois-plant-for-three-weeks/chr1UQZRd5b">Rivian Plans Shut Down Of Illinois Plant For Three Weeks, R2 Hopes Sparks Mixed Reactions Among Retail Investors</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’

MannKind will receive $75 million in cash at the closing of the agreement. 

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$4.88
Prev Close	$5.14
Open	$5.20
Dividend Yield	0.00%
50-Day Moving Average	$4.80
Beta	0.97
Avg. Volume	5.63M
PE Ratio	44.65

52-Week High	$7.63
52-Week Low	$3.38
Market Capitalization	$1.5B
EPS (Annual)	$0.0972
Price to Book	-27.16
Revenue Per Employee	$701,484.03
Enterprise Value/EBITDA	N/A

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNKD News

MNKDMannkind Corp